Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).
Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
Complejo Hospitalario de Pontevedra_Hospital Montecelo, Pontevedra, Spain
Hospital German Trias i Pujol, Badalona, Barcelona, Spain
Japan Cardiovascular Research Foundation, Suita, Osaka, Japan
University of Western Ontario, London, Canada
University of Ottawa, Ottawa, Canada
Ospedale di Circolo, Varese, Italy
OLV Hospital, Aalst, Belgium
Uniklinik, Aachen, Germany
Hamilton General Hospital, Hamilton, Ontario, Canada
The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
University of Alberta, Edmonton, Alberta, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.